Home Cart 0 Sign in  
X

[ CAS No. 502-44-3 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 502-44-3
Chemical Structure| 502-44-3
Chemical Structure| 502-44-3
Structure of 502-44-3 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 502-44-3 ]

Related Doc. of [ 502-44-3 ]

Alternatived Products of [ 502-44-3 ]

Product Details of [ 502-44-3 ]

CAS No. :502-44-3 MDL No. :MFCD00003267
Formula : C6H10O2 Boiling Point : -
Linear Structure Formula :- InChI Key :PAPBSGBWRJIAAV-UHFFFAOYSA-N
M.W : 114.14 Pubchem ID :10401
Synonyms :

Calculated chemistry of [ 502-44-3 ]

Physicochemical Properties

Num. heavy atoms : 8
Num. arom. heavy atoms : 0
Fraction Csp3 : 0.83
Num. rotatable bonds : 0
Num. H-bond acceptors : 2.0
Num. H-bond donors : 0.0
Molar Refractivity : 30.13
TPSA : 26.3 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.99 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.53
Log Po/w (XLOGP3) : 0.01
Log Po/w (WLOGP) : 1.1
Log Po/w (MLOGP) : 0.88
Log Po/w (SILICOS-IT) : 1.87
Consensus Log Po/w : 1.08

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -0.55
Solubility : 31.9 mg/ml ; 0.279 mol/l
Class : Very soluble
Log S (Ali) : -0.11
Solubility : 87.8 mg/ml ; 0.769 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -1.12
Solubility : 8.68 mg/ml ; 0.076 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.51

Safety of [ 502-44-3 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P305+P351+P338 UN#:N/A
Hazard Statements:H319 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 502-44-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 502-44-3 ]
  • Downstream synthetic route of [ 502-44-3 ]

[ 502-44-3 ] Synthesis Path-Upstream   1~8

  • 1
  • [ 502-44-3 ]
  • [ 4224-70-8 ]
YieldReaction ConditionsOperation in experiment
92% With sulfuric acid; hydrogen bromide In water for 12 h; Inert atmosphere; Reflux General procedure: Typical procedure: Under a dry argon atmosphere, 48percent HBr aqueous solution (41.0mL, 360mmol) and conc. sulfuric acid (9.6mL) were added dropwise to γ-butyrolactone (3a) (6.10g, 70.9mmol), and the resulting mixture was left undisturbed at room temperature for 2h. Then, after refluxing for 12h, the reaction mixture was cooled to room temperature. To this reaction mixture, 192mL of water was added, and the crude product was extracted with diethyl ether. The combined organic layer was washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography eluted with a mixed solvent of ethyl acetate/hexane (1/2v/v). The fraction with an Rf value of 0.44 was collected and dried under reduced pressure to afford 4-bromobutanoic acid (4a) as yellow oil (7.638g, 65percent)
82% at 20℃; for 7 h; Reflux General procedure: 4-Butyrolactone (1) (48.2 g, 0.56 mol, 1 equiv) was dissolved in a mixture of 48percent HBr solution (317 mL, 2.8 mol, 5 equiv) and conc H2SO4 (76 mL, 1.4 mol, 2.5 equiv) and left at room temperature for 2 h. The mixture was refluxed for 5 h, cooled to room temperature and poured to 1.5 L distilled water. The mixture was extracted with diethyl ether, washed with brine, dried over Na2SO4 and concentrated. Distillation of the crude product under reduced pressure (7 mbar) gave 57.0 g (61percent) of colourless oil
Reference: [1] Reactive and Functional Polymers, 2016, vol. 99, p. 1 - 8
[2] Bioorganic and Medicinal Chemistry, 2011, vol. 19, # 1, p. 567 - 579
[3] Bioorganic and Medicinal Chemistry, 2006, vol. 14, # 9, p. 2896 - 2903
[4] Bioorganic and Medicinal Chemistry, 2006, vol. 14, # 23, p. 7681 - 7687
[5] Journal of the American Chemical Society, 1982, vol. 104, # 5, p. 1391 - 1403
[6] Journal of Organic Chemistry, 1975, vol. 40, # 23, p. 3456 - 3458
[7] Tetrahedron Letters, 1981, vol. 22, # 50, p. 5101 - 5104
[8] Journal of the American Chemical Society, 1981, vol. 103, # 17, p. 5183 - 5189
[9] Synthesis, 2008, # 20, p. 3229 - 3236
[10] Beilstein Journal of Organic Chemistry, 2011, vol. 7, p. 1342 - 1346
  • 2
  • [ 502-44-3 ]
  • [ 67-56-1 ]
  • [ 14273-90-6 ]
Reference: [1] Canadian Journal of Chemistry, 2003, vol. 81, # 8, p. 937 - 960
[2] Journal of the American Chemical Society, 2014, vol. 136, # 41, p. 14389 - 14392
[3] Bulletin de la Societe Chimique de France, 1972, p. 4163 - 4170
[4] Synthesis, 1977, p. 112 - 113
  • 3
  • [ 502-44-3 ]
  • [ 14273-90-6 ]
Reference: [1] Reactive and Functional Polymers, 2016, vol. 99, p. 1 - 8
  • 4
  • [ 502-44-3 ]
  • [ 25542-62-5 ]
Reference: [1] Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1985, vol. 24, p. 1081 - 1083
[2] Canadian Journal of Chemistry, 1983, vol. 61, p. 2016 - 2021
  • 5
  • [ 108-94-1 ]
  • [ 502-44-3 ]
  • [ 124-04-9 ]
  • [ 693-23-2 ]
  • [ 50905-10-7 ]
  • [ 32673-76-0 ]
  • [ 142-62-1 ]
Reference: [1] Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation), 1986, vol. 35, # 1, p. 72 - 75[2] Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya, 1986, # 1, p. 85 - 88
  • 6
  • [ 502-44-3 ]
  • [ 25775-90-0 ]
Reference: [1] Journal of Organic Chemistry, 1988, vol. 53, # 5, p. 1064 - 1071
  • 7
  • [ 502-44-3 ]
  • [ 6399-81-1 ]
  • [ 50889-29-7 ]
Reference: [1] Chemical and Pharmaceutical Bulletin, 1997, vol. 45, # 4, p. 685 - 696
  • 8
  • [ 502-44-3 ]
  • [ 50889-29-7 ]
Reference: [1] Beilstein Journal of Organic Chemistry, 2011, vol. 7, p. 1342 - 1346
Same Skeleton Products
Historical Records